

Now, almost 3 years ago...

ADAURA Phase III double-blind study design

Patients with completely resected stage* IB, II, IIIA NSCLC, with or without adjuvant chemotherapy†

- Key inclusion criteria:
- ≥18 years (Japan / Taiwan: ≥20)
 - WHO performance status 0 / 1
 - Confirmed primary non-squamous NSCLC Ex19del / L858R‡
 - Brain imaging, if not completed pre-operatively
 - Complete resection with negative margins§
 - Max. interval between surgery and randomization:
 - 10 weeks without adjuvant chemotherapy
 - 26 weeks with adjuvant chemotherapy

Stratification by:
stage (IB vs II vs IIIA)
EGFRm (Ex19del vs L858R)
race (Asian vs non-Asian)

Osimertinib
80 mg, once daily

Randomization
1:1
(N=682)

Placebo,
once daily

Planned treatment duration: 3 years

Treatment continues until:

- Disease recurrence
- Treatment completed
- Discontinuation criterion met


Follow up:

- Until recurrence: Week 12 and 24, then every 24 weeks to 5 years, then yearly
- After recurrence: every 24 weeks for 5 years, then yearly

Endpoints

- **Primary:** DFS, by investigator assessment, in stage II/IIIA patients; designed for superiority under the assumed DFS HR of 0.70
- **Secondary:** DFS in the overall population¶, DFS at 2, 3, 4, and 5 years, OS, safety, health-related quality of life

Primary endpoint: DFS in patients with stage II/IIIA disease




On December 18, 2020, the Food and Drug Administration approved osimertinib (TAGRISSO, AstraZeneca Pharmaceuticals LP) for adjuvant therapy after tumor resection in patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.

Herbst R, ASCO 2020

Overall Survival: Patients With Stage II/IIIA Disease

- Adjuvant osimertinib demonstrated a statistically and clinically significant improvement in OS vs placebo in the primary population of Stage II-IIIa disease




Data cut-off: January 27, 2023.

Tick marks indicate censored data. Alpha allocation of 0.0497. ^aMedian follow-up for OS (all patients): osimertinib 59.9 months, placebo 56.2 months.

CI, confidence interval; HR, hazard ratio; OS, overall survival.

Overall Survival: Patients With Stage IB/II/IIIA Disease


- Adjuvant osimertinib demonstrated a statistically and clinically significant improvement in OS vs placebo in the overall population of Stage IB-IIIa disease



Data cut-off: January 27, 2023. Tick marks indicate censored data. Alpha allocation of 0.0497. ^aMedian follow-up for OS (all patients): osimertinib 60.4 months, placebo 59.4 months.

CI, confidence interval; HR, hazard ratio; OS, overall survival

OS Across Subgroups: Patients With Stage IB/II/IIIA Disease




Data cut-off: January 27, 2023.


*AJCC/UICC 7th edition.

AJCC/ UICC, American Joint Committee on Cancer/ UICC, Union for International Cancer Control; CI, confidence interval; EGFR, epidermal growth factor receptor; Ex19del, exon 19 deletion; HR, hazard ratio; OS, overall survival; PH, proportional-hazards model.

Overall Survival by Disease Stage




No. at risk	0	6	12	18	24	30	36	42	48	54	60	66	72	78	84	90
Osimertinib	106	103	101	100	98	97	96	96	94	82	61	39	17	6	0	-
Placebo	106	106	106	105	104	102	100	99	96	85	70	44	19	9	1	0



No. at risk	0	6	12	18	24	30	36	42	48	54	60	66	72	78	84	90
Osimertinib	118	116	112	112	112	109	104	104	100	83	61	36	19	4	0	-
Placebo	118	118	117	114	110	107	104	103	94	79	56					

	Stage IB	Stage II	Stage IIIA
5 year OS rate, % (95% CI)			
Osimertinib	94 (86, 97)	85 (77, 91)	85 (76, 91)
Placebo	88 (80, 93)	78 (69, 85)	67 (57, 75)
Overall HR (95% CI)	0.44 (0.17, 1.02)	0.63 (0.34, 1.12)	0.37 (0.20, 0.64)




No. at risk	0	6	12	18	24	30	36	42	48	54	60	66	72	78	84
Osimertinib	115	113	112	112	109	105	104	101	100	87	54	33	14	5	0


Data cut-off: January 27, 2023. Tick marks indicate censored data.

CI, confidence interval; HR, hazard ratio; OS, overall survival.

OS in Patients With and Without Adjuvant Chemotherapy: Patients With Stage IB/II/IIIA Disease



No. at risk	Time from randomization (months)															
	0	6	12	18	24	30	36	42	48	54	60	66	72	78	84	90
Osimertinib	203	200	197	197	196	192	188	185	182	155	104	58	25	7	0	-
Placebo	207	204	200	197	189	182	174	166	159	133	92	48	19	7	2	0



No. at risk	Time from randomization (months)															
	0	6	12	18	24	30	36	42	48	54	60	66	72	78	84	90
Osimertinib	136	132	128	127	123	119	116	116	112	97	72	50	25	8	0	-
Placebo	136	134	132	129	125	122	116	115	108	90	72	49	25	10	1	0

Data cut-off: January 27, 2023.

Overall population: stage IB/II/IIIA. Tick marks indicate censored data.

Use of adjuvant chemotherapy before randomization was allowed but not mandatory, decided by the physician and patient before enrollment.

CI, confidence interval; HR, hazard ratio; OS, overall survival.